These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12575618)

  • 41. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral rounds. A very discordant response.
    Henry K; Jenny-Avital E
    AIDS Clin Care; 2002 Jan; 14(1):4-5, 8. PubMed ID: 11802628
    [No Abstract]   [Full Text] [Related]  

  • 44. What's new and what's next.
    Fakuda D
    Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination study for children.
    Vazquez E
    Posit Aware; 1998; 9(1):15. PubMed ID: 11364991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

  • 49. [HIV infections: mortality reduced only in developed countries].
    Wehr A
    Dtsch Med Wochenschr; 1999 May; 124(18):A8-9. PubMed ID: 10356577
    [No Abstract]   [Full Text] [Related]  

  • 50. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 52. Antiretrovirals.
    Temesgen Z; Wright AJ
    Mayo Clin Proc; 1999 Dec; 74(12):1284-301. PubMed ID: 10593358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An unusual abacavir reaction.
    Fox J; Newton P; Daly R; Blume A; Marett B; Greene L; Winston A
    AIDS; 2008 Jul; 22(12):1520-2. PubMed ID: 18614878
    [No Abstract]   [Full Text] [Related]  

  • 55. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
    Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.
    Ndagijimana JM; Kroll H; Niehues T
    AIDS; 2002 Mar; 16(5):802-3. PubMed ID: 11964543
    [No Abstract]   [Full Text] [Related]  

  • 57. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
    Gervasoni C; Vigano O; Grinelli E; Ortu M; Galli M; Rusconi S
    AIDS Patient Care STDS; 2007 Jan; 21(1):1-3. PubMed ID: 17263652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myelomeningocele in a child with intrauterine exposure to efavirenz.
    Fundarò C; Genovese O; Rendeli C; Tamburrini E; Salvaggio E
    AIDS; 2002 Jan; 16(2):299-300. PubMed ID: 11807320
    [No Abstract]   [Full Text] [Related]  

  • 59. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
    Yazaki H; Kikuchi Y; Oka S
    Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
    [No Abstract]   [Full Text] [Related]  

  • 60. [Antiretroviral-induced toxiderma in HIV-infected patients].
    Caumes E; Bossi P; Katlama C; Bricaire F
    Presse Med; 2003 Sep; 32(28):1325-33. PubMed ID: 14506444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.